未知机构：何氏眼科投资者关系管理信息-20241206

Summary of the Conference Call for He Eye Hospital Group Co., Ltd. Company Overview - Company Name: He Eye Hospital Group Co., Ltd. - Stock Code: 301103 - Date of Conference Call: December 6, 2024 - Participants: Various private equity firms and analysts Key Points Discussed Industry and Business Expansion - The company is actively constructing a full lifecycle eye health management industry chain and is expanding its presence in key regions including Beijing-Tianjin-Hebei, Yangtze River Delta, Guangdong-Hong Kong-Macau Greater Bay Area, and Chengdu-Chongqing area [2] - The expansion strategy combines organic growth with investment and mergers and acquisitions [2] - A partnership has been established with Shenzhen招商国协贰号股权投资基金 and 茅台招华 (Guizhou)产业发展基金 to create a health technology industry development fund focusing on eye health [2] Pricing Strategy - Some diagnostic services, such as cataract and glaucoma treatments, are covered by medical insurance and managed according to insurance agreements [3] - For more consumer-oriented services like refractive and optometry services, a market-driven pricing strategy is employed [3] Advantages in Optometry Business - The optometry business has both medical and consumer attributes, with patient safety being a primary concern [3] - The company has over 20 years of experience in the eye health field, a mature physician training system, and a strong patient reputation [3] - Services offered include eye-related diagnostic services, myopia prevention for adolescents, medical optometry, and family eye health management [3] Myopia Prevention System - The company has developed a comprehensive "Myopia Prevention 365 System" that integrates school, family, and medical environments [3] - This system is based on six core technologies: environment, genetics, optics, eye load, behavior, and nutrition [3] Gene Therapy Market Position - The company is exploring gene therapy in areas such as hereditary retinal pigment degeneration and congenital cataracts [3] - It has accumulated experience in gene diagnosis and is applying gene testing technology in myopia prevention and refractive services [3] - Future innovations in precision medicine for difficult-to-treat eye diseases are planned [3] Additional Important Information - The company confirmed that no undisclosed significant information was leaked during the conference call [4]